Treatment of depression in first episode of schizophrenia: Results from EUFEST

Rybakowski, Janusz; Vansteelandt, Kristof; Szafrański, Tomasz; Thys, É.; Jarema, Marek; Fleischhacker, W. Wolfgang; Kahn, René S.; Peuskens, Joseph

doi:10.1016/j.euroneuro.2012.04.001

Cited by 25 publications

(16 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In line with previous findings, 28% of clinical sample reported clinical depression according to CDSS cut-off point of > 6 ( Dan et al, 2011;Rybakowski et al, 2012). From a psychopathological perspective, we found that both personal resources and negative symptoms concurred to depression.…”

Section: Discussionsupporting

confidence: 91%

“…The CDSS includes nine items (depression, hopelessness, self-depreciation, guilty ideas of reference, pathological guilt, morning depression, early wakening, suicide, observed depression), each rated from 0 (absent) to 3 (severe). Ratings > 6 on the total score indicate clinically significant depression (Rybakowski et al, 2012). The Italian translation of the CDSS is available on the official website (http://www.ucalgary.ca/ cdss/).…”

Section: Dependent Variablementioning

confidence: 99%

See 1 more Smart Citation

Personal resources and depression in schizophrenia: The role of self-esteem, resilience and internalized stigma

Rossi

Galderisi

Rocca

et al. 2017

Psychiatry Research

View full text Add to dashboard Cite

Depression in schizophrenia represents a challenge from a diagnostic, psychopathological and therapeutic perspective. The objective of this study is to test the hypothesis that resilience and self-stigma affect depression severity and to evaluate the strength of their relations in 921 patients with schizophrenia. A structural equation model was tested where depression is hypothesized as affected by resilience, internalized stigma, gender and negative symptoms, with the latter two variables used as exogenous covariates and the former two as mediators. The analysis reveals that low resilience, high negative symptoms, female gender were directly associated with depression severity, and internalized stigma acted only as a mediator between avolition and resilience, with similar magnitude. The cross-sectional study design and the variable selection limit the generalizability of the study results. The model supports a complex interaction between personal resources and negative symptoms in predicting depression in schizophrenia. The clinical implication of these findings is that personal resources could be a significant target of psychosocial treatments.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Dependent Variablementioning

confidence: 99%

Personal resources and depression in schizophrenia: The role of self-esteem, resilience and internalized stigma

Rossi

Galderisi

Rocca

et al. 2017

Psychiatry Research

View full text Add to dashboard Cite

show abstract

“…The non‐pharmaceutical industry‐sponsored Clinical Antipsychotic Trials of Intervention Effectiveness, involving 1460 patients with chronic schizophrenia, did not show any difference between the atypical antipsychotics and the typical comparator, perphenazine, on depressive symptoms 20 . A re‐analysis of the European First Episode Schizophrenia Trial found that over the 1‐year course of the study, there was no differential effect of atypical antipsychotics (olanzapine, quetiapine, amisulpride, ziprasidone) or low‐dose haloperidol on depression, irrespective of whether concomitant antidepressants were used 21 . In clinical trials, the most consistent effects of atypical antipsychotics for treating depressive symptoms in schizophrenia have been reported for quetiapine 22 ‐ 24 and olanzapine 25 , 26 .…”

Section: Managementmentioning

confidence: 98%

Schizophrenia and depression

Bosanac

Castle

2013

Medical Journal of Australia

View full text Add to dashboard Cite

Summary Depressive symptoms are common in people with schizophrenia and can be associated with suicidality, but are often either missed or dismissed by clinicians. General practitioners have a key role in initial assessment and subsequent monitoring of depressive symptoms, associated risks and physical health in patients with schizophrenia. Liaison with appropriate non‐government organisations and public or private specialist mental health services can enhance GPs’ management of depression in schizophrenia. Antidepressants, prescribed in tandem with antipsychotics, have a likely therapeutic role for persistent depressive symptoms in schizophrenia, but side effects can be troublesome. Although some of the atypical antipsychotics appear to have primary antidepressant effects, the utility of these agents alone in the setting of persistent depressive symptoms in schizophrenia has not been established.

show abstract

“…Depression commonly occurs in patients with schizophrenia and has clinical significance. Few studies have demonstrated the possible clinical advantage of using antidepressants to manage depression in patients with schizophrenia, suggesting that the use of antidepressants is unreliable . The efficacy of treatment with antidepressants is restricted and antidepressants can aggravate psychosis during the acute phase .…”

mentioning

confidence: 99%

“…Few studies have demonstrated the possible clinical advantage of using antidepressants to manage depression in patients with schizophrenia, suggesting that the use of antidepressants is unreliable. 4 The efficacy of treatment with antidepressants is restricted and antidepressants can aggravate psychosis during the acute phase. 5 In addition, there is a hazard of pharmacokinetic interactions, particularly with selective serotonin reuptake inhibitors.…”

mentioning

confidence: 99%

Open prospective study of ziprasidone in patients with schizophrenia with depressive symptoms: A multicenter study

Jung

Kim

Lee

et al. 2014

Psychiatry Clin Neurosci

View full text Add to dashboard Cite

Aims:The goal of this study was to examine the efficacy and safety of ziprasidone to treat depressive symptoms in Korean patients with schizophrenia who showed stable symptoms. Methods:In this 8-week, open-label, prospective, non-randomized, multicenter study, 34 patients with schizophrenia who showed a stable response to previous medications, maintained a stable dose, and who had depressive symptoms, were recruited. Ziprasidone was the only antipsychotic agent allowed for 8 weeks after a 2-7-week washout period.Results: Steady decreases were observed on the Montgomery-Asberg Depression Rating Scale, the Calgary Depression Scale for Schizophrenia, the Positive and Negative Syndrome Scale, and the Clinical Global Impression-Severity Scale scores. The Montgomery-Asberg Depression Rating Scale score was 20.26 ± 4.77 at baseline and 12.21 ± 7.94 at the end-point (P < 0.01). The Calgary Depression Scale for Schizophrenia score was 9.76 ± 4.11 at baseline and 5.00 ± 3.94 at the end-point (P < 0.01). The Positive and Negative Syndrome Scale total score was 75.24 ± 22.63 at baseline and 66.53 ± 24.28 at the end-point (P < 0.01). The Clinical Global Impression-Severity Scale score was 3.44 ± 0.66 at baseline and 3.15 ± 0.86 at the end-point (P < 0.05). No significant differences were observed for total scores on the Simpson and Angus Rating Scale, the Barnes Akathisia Rating Scale, or the Abnormal Involuntary Movement Scale between the baseline and end-point. Conclusions:Ziprasidone was effective for improving depressive symptom scores and was well tolerated. Switching to ziprasidone is a good strategy in patients with schizophrenia who are experiencing depressive symptoms.

show abstract

Treatment of depression in first episode of schizophrenia: Results from EUFEST

Cited by 25 publications

References 44 publications

Personal resources and depression in schizophrenia: The role of self-esteem, resilience and internalized stigma

Personal resources and depression in schizophrenia: The role of self-esteem, resilience and internalized stigma

Schizophrenia and depression

Open prospective study of ziprasidone in patients with schizophrenia with depressive symptoms: A multicenter study

Contact Info

Product

Resources

About